Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
VivoSim Labs, Inc. - Common Stock
(NQ:
VIVS
)
0.3446
-0.0414 (-10.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about VivoSim Labs, Inc. - Common Stock
< Previous
1
2
Next >
In today's session, these stocks are experiencing unusual volume.
↗
July 21, 2026
Via
Chartmill
MissionIRNewsBreaks – VivoSim Labs, Inc. (NASDAQ: VIVS) Announces $4 Million Private Placement
July 21, 2026
Via
Investor Brand Network
Topics
Animal Testing
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
July 21, 2026
Initial customer wins bring VivoSim’s human-relevant liver and GI testing to the world’s second-largest pharmaceutical market
From
VivoSim Labs, Inc.
Via
GlobeNewswire
In today's session, these stocks are experiencing unusual volume.
↗
July 16, 2026
Via
Chartmill
Thursday's session: top gainers and losers
↗
July 16, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
July 16, 2026
Via
Chartmill
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
July 16, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
July 15, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
June 29, 2026
VivoSim Demonstrates Leadership in Field through AI-enabled NAMkind™ Liver and Intestine with High Accuracy Results, Including for Antibody Drug Conjugates (ADCs)
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
April 28, 2026
VivoSim’s NAMkind™ Intestinal Model combined with AI prediction tools yields high-accuracy results
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Which stocks are moving before the opening bell on Wednesday?
↗
April 01, 2026
Via
Chartmill
VivoSim Announces Pricing of up to a $4 Million Public Offering
April 01, 2026
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
March 24, 2026
ADCs are a major new market; Company demonstrates ability to discern antibody toxicity from payload toxicity and show differential linker chemistry toxicity
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
March 03, 2026
Veteran business development leader with deep expertise in human-relevant NAM and spheroid-based in vitro services to spearhead commercial growth along the US East Coast, deepening VivoSim’s reach with...
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
February 11, 2026
Company produces thorough reference testing on Antibody Drug Conjugates, showing high correlation with clinical liver and intestinal toxicity and side effects
From
VivoSim Labs, Inc.
Via
GlobeNewswire
Why Is VIVS Stock Up 79% Today?
↗
January 30, 2026
VivoSims said on Friday that it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind human-based toxicology services.
Via
Stocktwits
Topics
Animal Testing
Let's take a look at the stocks that are in motion in today's session.
↗
January 30, 2026
Via
Chartmill
Check out the stocks that are attracting the most attention and driving market activity.
↗
January 30, 2026
Via
Chartmill
Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session.
↗
January 30, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
January 30, 2026
Via
Chartmill
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
January 29, 2026
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance
From
VivoSim Labs, Inc.
Via
GlobeNewswire
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
January 06, 2026
Distinguished drug-development and biomarker leader to advance NAMkind™ scientific strategy, translational insights, and next-generation toxicology platforms
From
VivoSim Labs, Inc.
Via
GlobeNewswire
These stocks are moving in today's session
↗
October 30, 2025
Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Roadzen Inc. (NASDAQ: RDZN) Accelerates U.S. Expansion with Strategic Acquisition – Surges on Record Volume – More Stocks Inside
October 30, 2025
Via
AB Newswire
Topics
Artificial Intelligence
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
October 30, 2025
Via
Benzinga
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
↗
October 30, 2025
Via
Benzinga
Tuesday's session: top gainers and losers
↗
September 16, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
↗
September 16, 2025
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
↗
September 16, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
September 03, 2025
Via
Benzinga
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit